Repligen Corporation
RGEN
NASDAQ·Healthcare·Medical - Instruments & Supplies·Mkt cap $9.8B
$169.18
▼ -2.17%
P/E
704.92
Mkt Cap
$9.8B
52-Wk Range
$100.99–$188.73
52-Week Range
$100.99 - $188.73
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 48.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
2 risks
- Average volatility.
- Extreme premium - high expectations embedded
Growth
Strong growth ahead
Value
Extreme premium - high expectations embedded
Momentum
Hot
+42.1% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying RGEN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
JUL 28, 2026
Reported EPS of $0.54 vs $0.45 consensus (+20.8% surprise). Revenue of $204.1M vs $201.6M expected (+1.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+20.8%
Revenue trend · last 2Q
—
+12%
Q1 26
Q2 26
$194.3M
$204.1M
Margins · last 2Q
Gross
-48.3%
Operating
5.8%
Profit
2.5%
Wall Street consensus
6 analysts · 83% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
83%
Hold
17%
Sell
0%
Median Price Target
—
Latest: Citi · Jul 7, 2026
vs Industry
How RGEN stacks vs Medical - Instruments & Supplies
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.